Nutritional composition for preventing bronchitis
Patent Information
- Application Number
- JP2022104518
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2022-06-29
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-06-29
AI Technical Summary
There are no effective measures to prevent bronchitis, a disease that can progress to pneumonia and is particularly risky for infants and the elderly, and existing treatments focus on symptoms rather than prevention.
A nutritional composition containing N-acetylneuraminic acid, 6'-sialyllactose, α2,6 disialo N-linked sugar chains, and disialo N-linked sugar chains with specific structures is developed to prevent bronchitis by incorporating these components into infant and adult nutritional formulations.
The composition effectively reduces the risk of bronchitis in infants and adults by mimicking the protective effects of breast milk, providing a preventive solution for high-risk groups.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a nutritional composition for preventing bronchitis, and more particularly to a nutritional composition for preventing bronchitis, which contains N-acetylneuraminic acid as an active ingredient. [Background technology]
[0002] Bronchitis is a disease in which the airways (bronchi) where the trachea branches off are infected with viruses or bacteria, causing inflammation. Bronchitis is often caused by viral infections such as respiratory syncytial virus, rhinovirus, adenovirus, coronavirus, and influenza virus, but it can also be caused by bacterial pathogens such as mycoplasma and Bordetella pertussis. After the initial infection with these pathogens, bacteria such as Streptococcus pneumoniae and Haemophilus influenzae can cause secondary infections, making the condition more severe.
[0003] Infants are at high risk of contracting bronchitis because their immune systems are not yet fully mature. In particular, infants up to about three months of age have narrow bronchi that are weak at expelling phlegm, putting them at high risk of developing serious inflammation. Additionally, older people with weakened immune systems are also at high risk of developing bronchitis, which can progress to pneumonia, a serious and life-threatening condition.
[0004] Therefore, for everyone from infants to the elderly, preventing bronchitis is important for living a healthy social life, and various treatments and preventive methods have been studied. Regarding treatments after contracting bronchitis, administration of anti-influenza virus drugs, treatment with various antibiotics, treatment with cough suppressants and expectorants, etc. have been developed. Patent Document 1 discloses an antiulcer agent or a bifidobacterium growth promoter containing a specific sialic acid derivative as an active ingredient, and also shows the therapeutic effect on infectious diseases caused by viruses such as influenza virus, rotavirus, and herpes virus, but does not show the preventive effect on bronchitis. In addition, this patent document shows the prevention of diarrhea caused by rotavirus, but does not show the prevention of bronchitis because rotavirus is not the causative virus of bronchitis. As such, there is no effective measure for preventing bronchitis, and the only thing that can be done is to encourage general hand washing and gargling.
[0005] Incidentally, it is known that breast milk contains various components that reduce the risk of infectious diseases (Patent Document 2). In particular, it has been reported that carbohydrates, mainly oligosaccharides, contained in breast milk inhibit the stage at which certain viruses attach to host cells (Patent Document 3). In searching for an active ingredient that prevents the onset of bronchitis, the present inventors focused on the ingredients contained in breast milk. However, it is unclear whether it is possible to specifically prevent the onset of bronchitis itself, and it was not possible to infer what ingredients in breast milk are capable of preventing the onset of bronchitis. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Patent No. 3930559 [Patent Document 2] Patent No. 2514375 [Patent Document 3] Patent No. 3789146 Summary of the Invention [Problem to be solved by the invention]
[0007] The present inventors thought that if a component that prevents the onset of bronchitis could be found in breast milk, then it would be possible to provide a nutritional composition for infants that prevents the onset of bronchitis by incorporating the component into the nutritional composition for infants. Furthermore, since the component is effective not only for infants but also for the elderly and people with underlying diseases who are at high risk of bronchitis, it would also be possible to incorporate the component into foods and nutritional compositions for adults and the elderly and provide them as nutritional compositions that prevent the onset of bronchitis. An object of the present invention is to find components in breast milk that can prevent the onset of bronchitis, and to provide a new nutritional composition. [Means for solving the problem]
[0008] In order to search for components in breast milk that prevent the onset of bronchitis, the inventors statistically analyzed the relationship between the amount of carbohydrate components in breast milk and the infant's history of bronchitis, and conducted extensive research into new components that prevent the onset of bronchitis. As a result, they found that N-acetylneuraminic acid, 6'-sialyllactose, α2,6 disialo N-linked glycan, and disialo N-linked glycan with a specific structure in breast milk are effective in preventing bronchitis, thereby completing the present invention. That is, the present invention relates to a nutritional composition for preventing the onset of bronchitis, which is characterized by containing N-acetylneuraminic acid, 6'-sialyllactose, an α2,6 disialo N-linked glycan, and a disialo N-linked glycan with a specific structure as active ingredients. Specifically, the present invention has the following configuration.
[0009] <1> A nutritional composition for preventing bronchitis, comprising N-acetylneuraminic acid as an active ingredient. <2> The N-acetylneuraminic acid is bound to one or more of a protein, a peptide, an oligosaccharide, and a lipid. <1> The nutritional composition described in <3> The binding mode of N-acetylneuraminic acid is α2,6 bond <1> or <2> The nutritional composition described in <4> Sugar chains containing N-acetylneuraminic acid exist as 6'-sialyllactose <3> The nutritional composition described in <5> Sugar chains containing N-acetylneuraminic acid are N-linked glycans <3> The nutritional composition described in <6> The glycan containing N-acetylneuraminic acid is an α2,6 disialo N-linked glycan <5> The nutritional composition described in <7> The α2,6 disialo N-linked glycan has the following structure (1) or (2): <6> The nutritional composition described in (1)Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc (2)Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc <8> For infants and toddlers, <1> from <7> 13. The nutritional composition according to any one of claims 1 to 12. <9> <1> from <8> A food or drink for preventing bronchitis, comprising the nutritional composition for preventing bronchitis described in any one of the above. <10> <1> from <8> A pharmaceutical for preventing bronchitis, comprising the nutritional composition for preventing bronchitis described in any one of the above. Effect of the Invention
[0010] According to the present invention, the nutritional composition containing N-acetylneuraminic acid as an active ingredient can prevent the onset of bronchitis. Moreover, since the ingredient is effective not only for infants but also for the elderly and those with underlying diseases who are at high risk of bronchitis, it is possible to prevent the onset of bronchitis in adults and the elderly. [Brief description of the drawings]
[0011] [Figure 1]This shows the effect of N-acetylneuraminic acid concentration in breast milk on the incidence of bronchitis in infants. [Diagram 2] This shows the effect of 6'-SL concentration in breast milk on the incidence of bronchitis in infants. [Diagram 3] Figure 2 shows the effect of the concentration of disialo N-linked glycan A in breast milk on the incidence of bronchitis in infants. [Figure 4] Figure 2 shows the effect of the concentration of disialo N-linked glycan B in breast milk on the incidence of bronchitis in infants. [Diagram 5] This shows the effect of α2,6 disialo N-linked glycan concentrations in breast milk on the incidence of infant bronchitis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] (N-acetylneuraminic acid) The N-acetylneuraminic acid of the present invention may be in a free state or in a state bound to other sugars as oligosaccharides. In addition, the N-acetylneuraminic acid may be in a state bound to peptides and / or proteins or lipids. In addition, the N-acetylneuraminic acid may be derived from milk, eggs, bird's nests, or from a fermentation method of genetically modified bacteria, and may be any of synthetic products, semi-synthetic products, or natural products. In addition, natural materials containing natural products may be used as a supply source and blended into the nutritional composition of the present invention. Here, the natural product means a product extracted from a natural material containing N-acetylneuraminic acid by a known method, a crude product, or a product further highly purified from the above. For example, glycomacropeptide derived from milk, sialylglycopeptide obtained by concentrating the sugar chain portion of glycomacropeptide, etc. may be mentioned. In the present invention, the binding mode of N-acetylneuraminic acid is preferably an α2,6 bond. An α2,6-linked N-acetylneuraminic acid refers to an N-acetylneuraminic acid bound to a galactose residue or an N-acetylgalactosamine residue of an oligosaccharide or glycoprotein sugar chain via an α2,6 bond, and refers to a compound having a Neu5Acα2-6Gal structure or a Neu5Acα2-6GalNAc structure.
[0013] (6'-sialyllactose) In the present invention, the sugar chain containing N-acetylneuraminic acid is preferably present as 6'-sialyllactose (Neu5Acα2-6Galβ1-4Glc). 6'-sialyllactose (hereinafter sometimes simply referred to as 6'-SL) may be derived from milk or from the fermentation method of genetically modified bacteria, and may be any of synthetic products, semi-synthetic products, or natural products. In addition, natural materials containing natural products may be used as a supply source and incorporated into the nutritional composition of the present invention as they are. Here, the term "natural product" refers to a product extracted from a natural material containing 6'-sialyllactose by a known method, a crude product, or a product further purified from the above.
[0014] (N-linked glycan) In the present invention, the sugar chain containing N-acetylneuraminic acid is preferably present as an N-linked sugar chain. The N-linked sugar chain containing N-acetylneuraminic acid of the present invention may be in a free state or bound to a peptide and / or protein. It may also be derived from milk, eggs, meat, microorganisms, or fermentation of genetically modified bacteria, and may be a synthetic product, semi-synthetic product, or natural product. Natural materials containing natural products may be used as a supply source and blended into the nutritional composition of the present invention. Here, the natural product means a product extracted from a natural material containing an N-linked sugar chain by a known method, a crudely purified product, or a product further purified from the above.
[0015] (α2,6 disialo N-linked glycan) The α2,6 disialo N-linked glycan in the present invention refers to an N-linked glycan that reduces the incidence of bronchitis. The α2,6 disialo N-linked glycan of the present invention may be in a free state or bound to a peptide and / or protein. It may also be derived from milk, eggs, meat, microorganisms, or genetically modified bacteria fermentation, and may be a synthetic product, semi-synthetic product, or natural product. Natural materials containing natural products may be used as a supply source and added to the nutritional composition of the present invention. Here, the natural product means a product extracted from a natural material containing α2,6 disialo N-linked glycan by a known method, a crude product, or a product further purified by these.
[0016] Specifically, the α2,6 disialo N-linked glycan in the present invention includes Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc (hereinafter, sometimes simply referred to as disialo N-linked glycan A) and Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc (hereinafter, sometimes simply referred to as disialo N-linked glycan B), as well as, for example, Neu5Acα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-2Ma nα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc, Neu5Acα2-6Galβ1 -4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4 This refers to an N-linked glycan that has two Neu5Acα2,6 bonds at the non-reducing end, such as GlcNAc, Neu5Acα2-6Galβ1-4GlcNAcβ1-2 (Neu5Acα2-6Galβ1-4GlcNAcβ1-4)Manα1-3 (Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc.
[0017] The nutritional composition of the present invention must contain an effective amount of N-acetylneuraminic acid to prevent bronchitis, and the preferred range of the required amount per 100 g of solid matter of the nutritional composition is shown below. The N-acetylneuraminic acid is preferably 170 mg / 100 g solid or more, more preferably 189 mg / 100 g solid or more. When the nutritional composition is a powdered milk, the N-acetylneuraminic acid content in the prepared milk is preferably 221 mg / L or more, more preferably 246 mg / L or more. In addition, the nutritional composition of the present invention preferably contains 46.9 mg / 100 g solid or more of 6'-sialyllactose, more preferably 104 mg / 100 g solid or more. In addition, the milk after preparation preferably contains 61.0 mg / L or more of 6'-SL, more preferably 135 mg / L or more. In addition, the nutritional composition of the present invention preferably contains 0.198 μmol / 100 g solid or more of α2,6 disialo N-linked glycans, more preferably 0.338 μmol / 100 g solid or more. In addition, the milk after preparation preferably contains 0.257 μmol / L or more of α2,6 disialo N-linked glycans, more preferably 0.440 μmol / L or more. In addition, the nutritional composition of the present invention preferably contains 0.0728 μmol / 100 g solid or more of disialo N-linked glycan A, more preferably 0.241 μmol / 100 g solid or more. In addition, the milk after preparation preferably contains 0.0947 μmol / L or more of disialo N-linked glycan A, more preferably 0.313 μmol / L or more. In addition, the nutritional composition of the present invention preferably contains 0.0935 μmol / 100 g solid or more of disialo N-linked glycan B, more preferably 0.188 μmol / 100 g solid or more. In addition, the milk after preparation preferably contains 0.122 μmol / L or more of disialo N-linked glycan B, more preferably 0.245 μmol / L or more.
[0018] (Nutritional compositions, food and beverages, pharmaceuticals) The nutritional composition for preventing bronchitis of the present invention, which contains N-acetylneuraminic acid or the like as an active ingredient, may be any composition containing an effective amount of N-acetylneuraminic acid or the like, and may contain proteins, fats, carbohydrates, vitamins, minerals, etc. in addition to the active ingredient, and may be used as a nutritional composition for infants, as well as adults and the elderly. Nutritional compositions for infants and young children include infant formulas and liquid formulas, toddler formulas (follow-up milk and growing-up milk), formulas for low birth weight infants, allergen-free foods for those with cow's milk allergies, and lactose-free foods for those with lactose intolerance. Nutritional compositions for adults and the elderly include powdered milk formulas and liquid milk formulas for adults, allergen-free foods for those with milk allergies, lactose-free foods for those with lactose intolerance, and supplements. Furthermore, the food and drink of the present invention containing N-acetylneuraminic acid etc. for preventing bronchitis may be blended into any food and drink as long as it contains an effective amount of N-acetylneuraminic acid etc., or may be added to the raw materials during the manufacturing process of the food and drink. Examples of the food and drink include, but are not limited to, dairy products such as cheese, fermented milk, lactic acid bacteria drinks, butter, margarine, etc., beverages such as milk drinks, fruit juice drinks, and soft drinks, egg products such as jelly, candy, pudding, and mayonnaise, and sweets and breads such as butter cake, etc. The nutritional composition for preventing bronchitis of the present invention can be used as it is as a raw material for pharmaceuticals, and may be manufactured into tablets, capsules, powders, syrups, etc. by conventional methods. Therefore, when preparing a pharmaceutical product containing the composition for preventing bronchitis containing N-acetylneuraminic acid or the like of the present invention as an active ingredient, it can be formulated by appropriately mixing it with excipients, stabilizers, flavoring agents, etc. that are approved for formulation, or the composition containing N-acetylneuraminic acid or the like can be dried as it is and used as a powder or dust. It can also be formulated by mixing excipients, binders, disintegrants, lubricants, flavoring agents, suspending agents, coating agents, and other optional drugs within a range that does not impair the bronchitis prevention effect. The dosage form can be tablets, capsules, granules, powders, powders, syrups, etc. EXAMPLES
[0019] [Test Example 1] Various carbohydrate components were measured in 153 breast milk samples, and the relationship with the incidence of bronchitis in the first year of life was analyzed using logistic regression. The method and results are shown below.
[0020] 1. Method (1) Investigation of breast milk samples and infant infection histories In a prospective cohort study (UMIN ID 000015494) conducted by Snow Brand Bean-Stalk Co., Ltd. between 2014 and 2019 to investigate the relationship between breast milk components and the health status of mothers and children in Japan, breast milk samples collected from 1,210 mothers and questionnaire results investigating the health status of mothers and children were used in this study. In addition, 200 samples were randomly selected from the 1,210 samples. Breast milk collected between 1 and 2 months after birth was used as the breast milk samples for analysis. The questionnaire investigating the health status of infants was filled out by parents a total of six times every two months over the course of one year after birth, and the results were collected. From the questionnaire results, the results of whether or not the infant was diagnosed with bronchitis by a doctor within one year after birth were tallied. If the description of whether or not the infant had been diagnosed was unclear, the infant was excluded from the survey. As a result, 153 samples were properly answered regarding whether or not they had been diagnosed with bronchitis in a total of six questionnaires over the course of one year, and these were the subjects of analysis in this survey. Of the 153 samples, 18 were from infants diagnosed with bronchitis within one year of birth.
[0021] (2) Measurement of various carbohydrate components in breast milk (2-1) Measurement of total N-acetylneuraminic acid 800μL of ultrapure water and 100μL of 1N sulfuric acid were added to 100μL of breast milk from 153 samples to be analyzed, and then heated at 80℃ for 45 minutes. After cooling to room temperature and adding 1mL of 0.1N sodium hydroxide aqueous solution, ultrafiltration membrane treatment with a molecular weight cutoff of 10,000 was performed, and the permeate was analyzed by HPLC. For HPLC, a DIONEX ICS-5000DP system (Thermo Fisher Scientific Co., Ltd.) connected to an electrochemical detector and a CarboPac PA1 column (Thermo Fisher Scientific Co., Ltd.) were used. Three mobile phases were passed through the system at a flow rate of 1mL / min: ultrapure water (liquid A), 200mM sodium hydroxide solution (liquid B), and 100mM sodium hydroxide solution containing 600mM sodium acetate (liquid C). For the first 7 minutes, solution B was passed at 45% and solution C at 10%, after which solution B was linearly decreased to 37.5% by 10 minutes, and solution C was linearly increased to 25%. From 10 to 20 minutes, solution B was passed at 37.5% and solution C at 25%, and from 20.1 to 25 minutes, solution B was passed at 45% and solution C at 10%. The total amount of N-acetylneuraminic acid in each breast milk sample was calculated from a calibration curve created using a standard sample of N-acetylneuraminic acid with a known concentration.
[0022] (2-2) Measurement of oligosaccharides 580μL of ultrapure water was added to 20μL of breast milk from 153 samples to be analyzed, and then ultrafiltration with a molecular weight cutoff of 10,000 was performed, and the permeate was analyzed by HPLC. For the HPLC, a DIONEX ICS-5000DP system (Thermo Fisher Scientific Co., Ltd.) connected to an electrochemical detector and a CarboPac PA1 column (Thermo Fisher Scientific Co., Ltd.) were used. The mobile phase consisted of three solutions: ultrapure water (solution A), 200mM sodium hydroxide solution (solution B), and 100mM sodium hydroxide solution containing 600mM sodium acetate (solution C) at a flow rate of 1mL / min. Solution B was passed at 50% for 10 minutes from the start, and then solution B was linearly decreased to 47.5% by 18 minutes, and solution C was linearly increased to 5%. From 18 minutes to 28 minutes, solution B was passed at 47.5% and solution C was passed at 5%. From 28 minutes to 32 minutes, the concentration of solution B was linearly decreased to 42%, and solution C was linearly increased to 16%. From 32 minutes to 39 minutes, 42% solution B and 16% solution C were passed through, and then from 39 minutes to 43 minutes, 30% solution B and 40% solution C were passed through. The content of each oligosaccharide in each breast milk sample was calculated from a calibration curve prepared using standard products of known concentrations of 2'-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose (hereinafter sometimes simply referred to as 3'-SL), 6'-sialyllactose (hereinafter sometimes simply referred to as 6'-SL), lactodifucotetraose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-difucohexaose I, and lacto-N-difucohexaose II. The sum of these 11 types of oligosaccharides was defined as "total oligosaccharides."
[0023] (2-3) Measurement of N-linked glycans 10 μL of 3M sodium borohydride aqueous solution was added to 20 μL of breast milk from 153 samples to be analyzed, and the mixture was left to stand at room temperature for 30 minutes. Then, 7.5 μL of acetic acid was added and the mixture was left to stand at room temperature for 30 minutes. 15 μL of 1M ammonium bicarbonate aqueous solution and 7.5 μL of ultrapure water were added. Then, 5 μL of 400 mM dithiothreitol aqueous solution containing 5% sodium lauryl sulfate was added, and the mixture was heated at 100 °C for 10 minutes to denature the protein. The mixture was allowed to cool to room temperature, and 10 μL of 123 mM iodoacetamide aqueous solution was added and the mixture was left to stand at room temperature for 1 hour. After adding 7 μL of 500 mM sodium acetate aqueous solution (pH 6.0) and 9 μL of 10% NP-40 solution, 10 μL of 500 units / μL Peptide-N-glycanase F solution was added, and the mixture was left to stand at 37 °C for 24 hours to release N-linked glycans. After adding 109 μL of ultrapure water, the entire amount was introduced into Vivaspin 500 (Sartorius Co., Ltd.) with a molecular weight cutoff of 10,000, and centrifuged at 15,000 × g and 25 ° C for 10 minutes to recover the permeate. 50 μL of acetonitrile was added to 50 μL of the permeate and subjected to LC / MS analysis. LC / MS analysis was performed as follows. HPLC was performed using UltiMate 3000 (Thermo Fisher Scientific Co., Ltd.), and MS was performed using Q-Exactive (Thermo Fisher Scientific Co., Ltd.). The column used was GlycanPac AXH-1 (Thermo Fisher Scientific Co., Ltd.), and the column temperature was set to 40 ° C. The mobile phase used was acetonitrile (liquid A) and a 50 mM ammonium formate aqueous solution (liquid B) with a pH adjusted to 4.4, and the flow rate was 0.4 mL / min. After sample introduction, the ratio of solution B was increased linearly from 10% to 35% by 55 min, and then solution B was passed at 35% from 55 min to 65 min. The spray voltage of the ESI probe was 3.5 kV, the capillary temperature was 275°C, and nitrogen gas was used as the sheath gas, auxiliary gas, and collision gas. The S-Lens RF Level was set to 90. MS spectra were acquired by full scan measurement in the positive mode in the range of m / z 400-2000.The acquired MS spectra were analyzed using Compound Discover 2.1 (Thermo Fisher Scientific). Glycans were detected by comparing them with a glycan database constructed from previously reported N-linked glycans of milk proteins. In addition, an extraction chromatogram corresponding to the molecular ion peak of each glycan was created using Compound Discover, and the signal area value of each glycan detected in each breast milk sample was calculated. The calculated signal area value of the glycan was used as the relative quantitative value of each glycan. Sixteen types of N-linked glycans were detected, and the sum of their area values was used as the relative value of "total N-linked glycans."
[0024] (2-4) Measurement of O-linked glycans The 153 breast milk samples to be analyzed were added with the glycan release reagent included in the O-linked glycan analysis kit EZGlyco Prep kit (Sumitomo Bakelite Co., Ltd.) and heated at 50°C for 20 minutes. After dilution with ultrapure water, the mixture was introduced into a Vivaspin 500 with a molecular weight cutoff of 10,000, centrifuged at 15,000×g and 25°C for 15 minutes, and the permeate was collected. 50 μL of the permeate was added with 50 μL of acetonitrile and subjected to LC / MS analysis. The HPLC was performed using an UltiMate 3000, and the MS was performed using a Q-Exactive. The column used was a GlycanPac AXH-1, and the column temperature was set to 40°C. The mobile phase used was acetonitrile (liquid A) and a 50 mM ammonium formate aqueous solution (liquid B) with a pH adjusted to 4.4, and the flow rate was 0.4 mL / min. After sample introduction, the proportion of solution B was increased linearly from 10% to 35% by 55 minutes, and then solution B was passed at 35% from 55 minutes to 65 minutes. The spray voltage of the ESI probe was 3.5 kV, the capillary temperature was 275°C, and nitrogen gas was used for the sheath gas, auxiliary gas, and collision gas. The S-Lens RF Level was set to 90. MS spectra were acquired by full scan measurement in the range of m / z 300-2000 in positive mode. The acquired MS spectra were analyzed using Compound Discover 2.1 (Thermo Fisher Scientific Co., Ltd.). Glycans were detected by matching with the O-linked glycan database. In addition, an extraction chromatogram corresponding to the molecular ion peak of each glycan was created by Compound Discover, and the signal area value of each glycan detected in each breast milk sample was calculated. The calculated signal area value of the glycan was used as the relative quantitative value of each glycan. Twelve types of O-linked glycans were detected, and the sum of their area values was taken as the relative value for "total O-linked glycans."
[0025] (3) Structural determination of disialo N-linked glycan A and disialo N-linked glycan B (3-1) Structural analysis One of the 153 samples prepared in the above "Measurement of N-linked glycans" was subjected to LC / MS / MS measurement, and the structures of disialo N-linked glycan A and disialo N-linked glycan B were analyzed. LC / MS / MS analysis was performed as follows. An UltiMate 3000 was used for HPLC, and a Q-Exactive was used for MS. A GlycanPac AXH-1 was used as the column, and the column temperature was set at 40°C. Acetonitrile (liquid A) and a 50 mM ammonium formate aqueous solution (liquid B) adjusted to pH 4.4 were used as the mobile phase, and the flow rate was 0.4 mL / min. After sample introduction, the proportion of liquid B was increased linearly from 10% to 35% by 55 minutes, and then 35% of liquid B was passed from 55 minutes to 65 minutes. The spray voltage of the ESI probe was 3.5 kV, the capillary temperature was 275°C, and nitrogen gas was used as the sheath gas, auxiliary gas, and collision gas. The S-Lens RF Level was set to 90. MS / MS spectra were acquired in positive mode and data-dependent Top10 mode. The acquired MS / MS spectra were analyzed using SimGlycan Software (PREMIER Biosoft International), and the structures of disialo N-linked glycan A and disialo N-linked glycan B were analyzed.
[0026] (3-2) Determination of binding mode In addition, to determine the bond type of N-acetylneuraminic acid in disialo N-linked glycan A and disialo N-linked glycan B, they were treated with either sialidase that specifically degrades α2,3 bonds or sialidase that degrades both α2,3 and α2,6 bonds, and then analyzed by LC / MS. For one sample identical to that in (3-1) above, 37 μL of ultrapure water and 5 μL of the buffer solution included with the enzyme were added to 5 μL of N-linked glycan solution. 3 μL of α2,3-Sialidase or Neuraminidase diluted 10-fold with the buffer solution included with the enzyme was added and incubated at 37°C for 15 minutes. After heating in boiling water for 5 minutes to inactivate the enzyme, 50 μL of acetonitrile was added and subjected to LC / MS analysis. LC / MS analysis was performed as follows. An UltiMate 3000 HPLC system and a Q-Exactive MS system were used. The column used was a GlycanPac AXH-1, and the column temperature was set to 40°C. The mobile phase was acetonitrile (liquid A) and a 50 mM aqueous ammonium formate solution (liquid B) adjusted to pH 4.4, and the flow rate was 0.4 mL / min. After sample introduction, the proportion of liquid B was increased linearly from 10% to 35% by 55 minutes, and then 35% of liquid B was passed from 55 minutes to 65 minutes. The spray voltage of the ESI probe was 3.5 kV, the capillary temperature was 275°C, and nitrogen gas was used as the sheath gas, auxiliary gas, and collision gas. The S-Lens RF Level was set to 90. The acquired MS spectra were analyzed using Xcalibur software (Thermo Fisher Scientific Co., Ltd.).
[0027] (4) Absolute quantification of disialo N-linked glycans A and B The absolute amounts of disialo N-linked glycan A and disialo N-linked glycan B in breast milk, which were found to be associated with bronchitis, were measured. The content of disialo N-linked glycan A in breast milk was measured by the standard addition method using a standard substance of disialo N-linked glycopeptide. The absolute amount of disialo N-linked glycan B in breast milk was calculated by multiplying the absolute amount of disialo N-linked glycan A by the relative ratio of the area value of disialo N-linked glycan B to the area value of disialo N-linked glycan A obtained from the LC / MS results.
[0028] The method for measuring disialo N-linked glycan A by the standard addition method is described below. 10 μL of 3M sodium borohydride aqueous solution was added to 20 μL of breast milk from one sample randomly selected from 153 breast milk samples to be analyzed, and the sample was left to stand at room temperature for 30 minutes. Next, 7.5 μL of acetic acid was added and the sample was left to stand at room temperature for 30 minutes. 15 μL of 1M ammonium bicarbonate aqueous solution was added, followed by 7.5, 5.5, 3.5, or 1.5 μL of ultrapure water. In addition, 0, 2, 4, or 6 μL of an aqueous solution of sialyl glycopeptide (Tokyo Chemical Industry Co., Ltd.), which was used as a standard substance for glycopeptides bound to disialo N-linked glycan A, was added. Next, 5 μL of 120 mM dithiothreitol aqueous solution was added, and the sample was heated at 60°C for 30 minutes, after which 10 μL of 123 mM iodoacetamide aqueous solution was added and the sample was left to stand at room temperature for 1 hour. 20 μL of 40 units / μL trypsin solution was added and incubated at 37°C for 1 hour. Trypsin was inactivated by heating at 100°C for 5 minutes, and then 500 units / μL Peptide-N-glycanase F solution was added and left at 37°C for 18 hours to release N-linked glycans. The released N-linked glycans were labeled with 2-aminobenzamide and purified using the N-linked glycan preparation kit BlotGlyco (Sumitomo Bakelite), and then subjected to LC / MS analysis. The HPLC was performed on an UltiMate 3000 and the MS on a Q-Exactive. The column used was a GlycanPac AXH-1, and the column temperature was set at 40°C. The mobile phase used was acetonitrile (solution A) and a 50 mM ammonium formate solution (solution B) adjusted to pH 4.4, and the flow rate was 0.4 mL / min. After sample introduction, the ratio of solution B was increased linearly from 10% to 35% by 55 min, and then solution B was passed at 35% from 55 min to 65 min. The spray voltage of the ESI probe was 3.5 kV, the capillary temperature was 275°C, and nitrogen gas was used as the sheath gas, auxiliary gas, and collision gas. The S-Lens RF Level was set to 90. MS measurements were performed in positive mode by selected ion monitoring of m / z 1172.43. The acquired MS chromatograms were analyzed using Xcalibur software.The amount of disialyl N-linked glycan A in breast milk was absolutely quantified by the standard addition method by plotting the area value of the MS chromatogram against the amount of added sialyl glycopeptide. The absolute quantitative value of disialyl N-linked glycan A in each of the 153 breast milk samples was obtained using this absolute quantitative value and the relative quantitative value of the 153 breast milk samples obtained by the above-mentioned "Measurement of N-linked glycan". In addition, the absolute quantitative value of disialyl N-linked glycan B was obtained from the ratio of the area value of the MS chromatogram of disialyl N-linked glycan B to disialyl N-linked glycan A for each breast milk sample.
[0029] (5) Analysis of the relationship between the content of various carbohydrate components in breast milk and bronchitis The relationship between the concentrations of N-acetylneuraminic acid, oligosaccharides, N-linked glycans, O-linked glycans, disialo N-linked glycans A, and disialo N-linked glycans B and the incidence of infant bronchitis was analyzed by logistic regression in 153 breast milk samples. Adjustment factors included the sex of the infant, the presence or absence of siblings, method of delivery (natural birth, Caesarean section), and birth weight.
[0030] 2.Results (1) The relationship between the carbohydrate content of breast milk and the incidence of bronchitis in infants The relationship between the content of various carbohydrate components (total N-acetylneuraminic acid, total oligosaccharides, total N-linked glycans, and total O-linked glycans) and the incidence of bronchitis in infants was analyzed by logistic regression for 153 breast milk samples. As a result, a statistically significant relationship was observed between the concentration of total N-acetylneuraminic acid and the incidence of bronchitis (Table 1). On the other hand, no such relationship was observed for total oligosaccharides, total N-linked glycans, or total O-linked glycans. The odds ratio and regression coefficient between the concentration of total N-acetylneuraminic acid and the incidence of bronchitis were 0.098 and -2.32, respectively, indicating that infants who drank breast milk with a high concentration of total N-acetylneuraminic acid had a lower risk of developing bronchitis.
[0031] [Table 1]
[0032] Breast milk samples were divided into two groups based on whether the infants had bronchitis, and the total N-acetylneuraminic acid concentration in breast milk was compared. The breast milk of infants without bronchitis had a significantly higher total N-acetylneuraminic acid concentration than the breast milk of infants with bronchitis (Figure 1). This indicates that an infant nutritional composition containing the same level of N-acetylneuraminic acid as that of breast milk of infants without bronchitis is effective in reducing the risk of bronchitis. The distribution range of the total N-acetylneuraminic acid concentration in breast milk of infants without bronchitis was 181 to 977 mg / L, with a median of 395 mg / L (Table 2). The distribution of the total N-acetylneuraminic acid concentration was a distribution that showed a wider tail toward the higher concentration side, unlike a normal distribution. This distribution is also observed in the distribution of height and weight of infants, and when creating growth curves for infants, the 3rd to 97th percentile of the overall distribution is used as the standard (2000 Infant Physical Development Survey Report). Based on this, the 3rd to 97th percentile was used as the standard range for the total N-acetylneuraminic acid concentration in breast milk. The minimum total N-acetylneuraminic acid concentration in breast milk drunk by infants who did not suffer from bronchitis was 221 mg / L, which corresponds to the 3rd percentile of the distribution. In addition, the total N-acetylneuraminic acid content in breast milk was divided into two groups, samples with a total N-acetylneuraminic acid content of 246 mg / L or more and samples with a total N-acetylneuraminic acid content of 246 mg / L or less, and the relationship with the presence or absence of bronchitis was subjected to Fisher's exact probability test, with p<0.05 or less, indicating that a total N-acetylneuraminic acid content of 246 mg / L or more in breast milk reduces the risk of suffering from bronchitis. Therefore, for an infant nutritional composition that prevents the onset of bronchitis, it is necessary that the milk after preparation contains 221 mg / L or more of N-acetylneuraminic acid, preferably 246 mg / L or more. If the concentration of the prepared milk is 13%, it is necessary to incorporate at least 170 mg or more of N-acetylneuraminic acid per 100 g of solid matter in the infant nutritional composition, and it is preferable to incorporate at least 189 mg or more of N-acetylneuraminic acid. In addition, because the mechanism of bronchitis is the same in infants and adults, the formula of this nutritional composition for infants is also considered to be effective for adults and the elderly who are at high risk of bronchitis. Therefore, it is also effective as a nutritional composition for adults with the same N-acetylneuraminic acid content as above.
[0033] [Table 2]
[0034] (2) Discovery of N-acetylneuraminic acid compounds that prevent bronchitis in infants These results suggest that infants who drink breast milk with a high total N-acetylneuraminic acid content have a lower risk of developing bronchitis. As most N-acetylneuraminic acid in breast milk exists as oligosaccharides or sugar chains on glycoproteins, we investigated what molecular form of N-acetylneuraminic acid is involved in the prevention of bronchitis.
[0035] We analyzed the association between the concentrations of oligosaccharides bound to N-acetylneuraminic acid (2 types), N-linked glycans bound to N-acetylneuraminic acid (6 types), and O-linked glycans bound to N-acetylneuraminic acid (5 types) detected in breast milk and the incidence of infant bronchitis using logistic regression. Some of the analysis results are shown in Table 3. The analysis showed a statistically significant association between 6'-SL (p=0.035), disialo N-linked glycan A (p=0.038), and disialo N-linked glycan B (p=0.046) and the incidence of bronchitis, whereas no such association was observed with the content of 3'-SL. The regression coefficients between 6'-SL, disialo N-linked glycan A, and disialo N-linked glycan B and the incidence of bronchitis were negative and the odds ratios were less than 1, indicating that the risk of developing bronchitis is reduced in infants who drank breast milk with a high content of 6'-SL, disialo N-linked glycan A, and disialo N-linked glycan B.
[0036] [Table 3]
[0037] (3) Confirmation of the effectiveness of 6'-SL in preventing bronchitis in infants Breast milk samples were divided into two groups based on whether the infants had bronchitis, and the 6'-SL concentrations in the breast milk were compared. As a result, the amount of 6'-SL in the breast milk of infants without bronchitis was significantly higher than that of the breast milk of infants with bronchitis (Figure 2). This indicates that an infant nutritional composition containing a 6'-SL concentration equivalent to that of breast milk of infants without bronchitis is effective in reducing the risk of bronchitis in infant nutritional compositions. The distribution range of 6'-SL concentrations in breast milk of infants without bronchitis was 25.7 to 701 mg / L, with a median of 203 mg / L (Table 4). As with the distribution of N-acetylneuraminic acid, the distribution of 6'-SL concentrations in breast milk was not normal, but had a wider tail at higher concentrations, so the 3rd to 97th percentiles were used as the range of 6'-SL concentrations in breast milk. The 6'-SL concentrations in breast milk consumed by infants who did not suffer from bronchitis are considered to be 61.0 mg / L or higher, which corresponds to the 3rd percentile or higher. In addition, samples were divided into two groups, those with 6'-SL concentrations of 135 mg / L or higher and those with concentrations below 135 mg / L, and the relationship between the presence or absence of bronchitis was evaluated using Fisher's exact test, with a p<0.05 result, indicating that a 6'-SL concentration of 135 mg / L or higher in breast milk was associated with a lower risk of bronchitis.
[0038] [Table 4]
[0039] Therefore, as an infant nutritional composition that prevents the onset of bronchitis, it is necessary that the milk after preparation contains 61.0 mg / L or more of 6'-SL, and preferably 135 mg / L or more. If the concentration of the prepared milk is 13%, it is necessary to formulate a minimum of 46.9 mg or more of 6'-SL per 100 g of solid matter in the infant nutritional composition, and preferably 104 mg or more of 6'-SL is formulated. Since the mechanism of onset of bronchitis is the same in infants and adults, it is considered that the formulation of this infant nutritional composition is also effective for adults and elderly people who are at high risk of bronchitis. Therefore, it is also effective as a nutritional composition for adults that contains the same 6'-SL content as above.
[0040] (4) Confirmation of the preventive effect of disialo N-linked glycan A on bronchitis in infants Breast milk samples were divided into two groups based on whether the infants had bronchitis, and the concentration of disialo N-linked glycan A in breast milk was compared. As a result, the amount of disialo N-linked glycan A in breast milk drank by infants without bronchitis was significantly higher than that in breast milk drank by infants with bronchitis (Figure 3). This indicates that an infant nutritional composition containing a disialo N-linked glycan A concentration equivalent to that of breast milk drank by infants without bronchitis is effective in reducing the risk of bronchitis in infant nutritional compositions. The range of disialo N-linked glycan A concentration in breast milk drank by infants without bronchitis was 0.0740 to 2.88 μmol / L, with a median of 0.302 μmol / L (Table 4). As with the distribution of N-acetylneuraminic acid, the concentration distribution of disialo N-linked glycan A in breast milk was not a normal distribution, but was a distribution with a wider tail toward the higher concentration, so the 3rd to 97th percentile was set as the concentration range of disialo N-linked glycan A in breast milk. The disialo N-linked glycan A concentration in breast milk drunk by infants who did not suffer from bronchitis is considered to be 0.0947 μmol / L or more, which corresponds to the 3rd percentile or higher. In addition, the breast milk samples were divided into two groups, those with a disialo N-linked glycan A concentration of 0.313 μmol / L or more and those with a lower concentration, and the relationship with the presence or absence of bronchitis was evaluated using Fisher's exact probability test, with p<0.05, indicating that a breast milk disialo N-linked glycan A concentration of 0.313 μmol / L or more reduces the risk of bronchitis.
[0041] Therefore, as a nutritional composition for infants that prevents the onset of bronchitis, it is necessary that the milk after preparation contains 0.0947 μmol / L or more of disialo N-linked glycan A, preferably 0.313 μmol / L or more. If the concentration of the formula is 13%, it is necessary to incorporate at least 0.0728 μmol or more of disialo N-linked glycan A per 100 g of solid matter in the nutritional composition for infants, and preferably 0.241 μmol or more of disialo N-linked glycan A is incorporated. Since the mechanism of onset of bronchitis is the same in infants and adults, it is considered that the incorporation of this nutritional composition for infants is also effective for adults and elderly people who are at high risk of bronchitis. Therefore, it is also effective as a nutritional composition for adults that contains the same disialo N-linked glycan A content as above.
[0042] (5) Confirmation of the preventive effect of disialo N-linked glycan B on bronchitis in infants Breast milk samples were divided into two groups based on whether the infants had bronchitis, and the concentration of disialo N-linked glycan B in breast milk was compared. As a result, the amount of disialo N-linked glycan B in breast milk drank by infants who did not have bronchitis was significantly higher than that in breast milk drank by infants who had bronchitis (Figure 4). This indicates that an infant nutritional composition containing a disialo N-linked glycan B concentration at the same level as that of breast milk drank by infants who did not have bronchitis is effective in reducing the risk of bronchitis in infant nutritional compositions. The range of disialo N-linked glycan B concentration in breast milk drank by infants who did not have bronchitis was 0.0853 to 5.06 μmol / L, and the median was 0.599 μmol / L (Table 4). As with the distribution of N-acetylneuraminic acid, the distribution of disialo N-linked glycan B in breast milk was not a normal distribution, but was a distribution with a wider tail toward the higher concentration, so the 3rd to 97th percentile was set as the range of disialo N-linked glycan B in breast milk. The disialo N-linked glycan B concentration in breast milk drunk by infants who did not suffer from bronchitis is considered to be 0.122 μmol / L or more, which corresponds to the 3rd percentile or higher. In addition, samples were divided into two groups, samples with a disialo N-linked glycan B concentration of 0.245 μmol / L or more in breast milk and samples with a concentration of 0.245 μmol / L or less, and the relationship with the presence or absence of bronchitis was evaluated using Fisher's exact probability test, with p<0.05 or less, indicating that a breast milk disialo N-linked glycan B concentration of 0.245 μmol / L or more reduces the risk of bronchitis.
[0043] Therefore, as a nutritional composition for infants that prevents the onset of bronchitis, it is necessary that the milk after preparation contains 0.122 μmol / L or more of disialo N-linked glycan B, preferably 0.245 μmol / L or more. If the concentration of the formula is 13%, it is necessary to incorporate at least 0.0935 μmol or more of disialo N-linked glycan B per 100 g of solid matter of the nutritional composition for infants, and preferably 0.188 μmol or more of disialo N-linked glycan B. Since the mechanism of onset of bronchitis is the same in infants and adults, it is considered that the incorporation of this nutritional composition for infants is also effective for adults and elderly people who are at high risk of bronchitis. Therefore, it is also effective as a nutritional composition for adults that contains the same disialo N-linked glycan B content as above.
[0044] (6) Determination of the structures of disialo N-linked glycan A and disialo N-linked glycan B To investigate the structures of disialo N-linked glycan A and disialo N-linked glycan B in breast milk, which were found to be related to the incidence of infant bronchitis, the retention times of LC / MS chromatograms were compared with those of α2,3- or α2,6-linked disialo N-linked glycan standards. The retention times of both disialo N-linked glycan A and disialo N-linked glycan B were consistent with those of α2,6-disialo N-linked glycan standards. In addition, when disialo N-linked glycan A and disialo N-linked glycan B were treated with a non-specific sialidase, the glycans were decomposed, whereas when they were treated with a sialidase that specifically cleaves α2,3-linked N-acetylneuraminic acid, the glycans were not decomposed. This indicates that disialo N-linked glycan A and B are α2,6-disialo N-linked glycans represented by the following structure.
[0045] <Disialo N-linked glycan A> Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc <Disialo N-linked glycan B> Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc
[0046] (7) Confirmation of the preventive effect of α2,6 disialo N-linked glycans on bronchitis in infants The only difference between the sugar chain structures of disialo N-linked glycan A and disialo N-linked glycan B is whether or not one molecule of fucose is bound. Both have in common that two molecules of N-acetylneuraminic acid are α2,6-linked to galactose at the non-reducing end. Therefore, it was thought that N-linked glycans with this α2,6 disialo bond may be related to the onset of bronchitis in infants. Therefore, the association between the amount (molar concentration) of α2,6 disialo N-linked glycan in breast milk, which is the sum of the amounts (molar concentration) of disialo N-linked glycan A and disialo N-linked glycan B in breast milk, and bronchitis was analyzed by logistic regression. As a result, p=0.034, and it was found that there is a statistically significant association between the amount (molar concentration) of α2,6 disialo N-linked glycan in breast milk and the onset of bronchitis (Table 3). These associations had negative regression coefficients and odds ratios of less than 1, indicating that infants who drank breast milk with a high molar concentration of α2,6 disialo N-linked glycans had a reduced risk of developing bronchitis.
[0047] The breast milk samples were divided into two groups based on whether the infants had bronchitis, and the amount of α2,6 disialo N-linked glycans (molar concentration) in the breast milk was compared. As a result, the amount of α2,6 disialo N-linked glycans (molar concentration) in the breast milk of infants without bronchitis was significantly higher than that of infants with bronchitis (Figure 5). This indicates that an infant nutritional composition containing the same level of α2,6 disialo N-linked glycans as the breast milk of infants without bronchitis is effective in reducing the risk of bronchitis. The range of the distribution of the amount of α2,6 disialo N-linked glycans in the breast milk of infants without bronchitis was 0.179 to 6.76 μmol / L, with a median of 0.933 μmol / L (Table 4). As with the distribution of N-acetylneuraminic acid, the distribution of α2,6 disialo N-linked glycans in breast milk was not a normal distribution, but was a distribution with a wider tail toward higher concentrations, so the concentration range of α2,6 disialo N-linked glycans in breast milk was set to 3rd to 97th percentiles. The α2,6 disialo N-linked glycans in breast milk drunk by infants who did not suffer from bronchitis are considered to be 0.257 μmol / L or more, which corresponds to the 3rd percentile or higher. In addition, samples were divided into two groups, samples with α2,6 disialo N-linked glycans of 0.440 μmol / L or more, and samples with 0.440 μmol / L or less were used to evaluate the relationship with the presence or absence of bronchitis using Fisher's exact test, with p<0.05, indicating that α2,6 disialo N-linked glycans of 0.440 μmol / L or more in breast milk are associated with a lower risk of bronchitis.
[0048] Therefore, as an infant nutritional composition that prevents the onset of bronchitis, it is necessary that the milk after preparation contains 0.257 μmol / L or more of α2,6 disialo N-linked glycans, preferably 0.440 μmol / L or more. If the concentration of the formula is 13%, it is necessary to incorporate at least 0.198 μmol or more of α2,6 disialo N-linked glycans per 100 g of solids in the infant nutritional composition, preferably 0.338 μmol or more of α2,6 disialo N-linked glycans. Since the mechanism of onset of bronchitis is the same in infants and adults, it is considered that the incorporation of this infant nutritional composition is also effective for adults and elderly people who are at high risk of bronchitis. Therefore, it is also effective as a nutritional composition for adults that contains the same α2,6 disialo N-linked glycans as above.
[0049] [Example 1] Preparation of N-acetylneuraminic acid-containing infant formula 52.7 kg of whey powder, 239 kg of skim milk, and 28 g of N-acetylneuraminic acid were dissolved in 500 kg of water, and this solution was mixed with 23.9 kg of vegetable oil and homogenized. The resulting solution was sterilized, concentrated and dried by a standard method to obtain 99 kg of milk powder. The milk powder was mixed with 1 kg of vitamin and mineral ingredients to obtain 100 kg of milk powder. The amount of N-acetylneuraminic acid in the resulting milk powder was 221 mg / 100 g solid.
[0050] [Example 2] Preparation of 6'-sialyllactose-containing infant formula 52.7 kg of whey powder, 239 kg of skim milk, and 50 g of 6'-sialyllactose were dissolved in 500 kg of water, and this solution was mixed with 23.9 kg of vegetable oil and homogenized. The resulting solution was sterilized, concentrated and dried by a conventional method to obtain 99 kg of milk powder. The milk powder was mixed with 1 kg of vitamin and mineral components to obtain 100 kg of milk powder. The amount of 6'-sialyllactose in the resulting milk powder was 50 mg / 100 g solid.
[0051] [Example 3] Preparation of powdered milk containing glycopeptides 52.7 kg of whey powder, 239 kg of skim milk, and 567 mg of sialyl glycopeptide were dissolved in 500 kg of water, and this solution was mixed with 23.9 kg of vegetable oil and homogenized. The resulting solution was sterilized, concentrated, and dried by a standard method to obtain 99 kg of milk powder. The milk powder was mixed with 1 kg of vitamin and mineral ingredients to finally obtain 100 kg of modified milk powder. The α2,6 disialo N-linked glycan of the obtained milk powder was 0.198 μmol / 100 g solid.
[0052] [Example 4] Preparation of powdered milk containing glycopeptides 52.7 kg of whey powder, 239 kg of skim milk, and 421 g of egg yolk powder were dissolved in 500 kg of water, and this solution was mixed with 23.9 kg of vegetable oil and homogenized. The resulting solution was sterilized, concentrated, and dried by a standard method to obtain 99 kg of milk powder. The milk powder was mixed with 1 kg of vitamin and mineral ingredients to finally obtain 100 kg of modified milk powder. The α2,6 disialo N-linked glycan of the obtained milk powder was 0.198 μmol / 100 g solid.
[0053] [Example 5] Production of supplements 1 g of N-acetylneuraminic acid powder was mixed with 40 g of an equal mixture of vitamin C and citric acid, 100 g of granulated sugar, and 60 g of an equal mixture of cornstarch and lactose. The mixture was packed into a stick bag to produce the bronchitis prevention supplement of the present invention.
[0054] [Example 6] Production of supplements 10 mg of α2,6 disialo N-linked glycan was mixed with 40 g of an equal mixture of vitamin C and citric acid, 100 g of granulated sugar, and 60 g of an equal mixture of cornstarch and lactose. The mixture was packed into a stick bag to produce the bronchitis prevention supplement of the present invention.
[0055] [Example 7] Production of beverages The ingredients were mixed according to the composition shown in Table 5, filled into containers, and then heat sterilized to produce the beverage for preventing bronchitis of the present invention.
[0056] [Table 5]
[0057] [Example 8] Production of beverages The ingredients were mixed according to the composition shown in Table 6, filled into containers, and then heat sterilized to produce the beverage for preventing bronchitis of the present invention.
[0058] [Table 6] [Industrial Applicability]
[0059] According to the present invention, the nutritional composition containing N-acetylneuraminic acid as an active ingredient can prevent the onset of bronchitis. Moreover, since the ingredient is effective not only for infants but also for the elderly and those with underlying diseases who are at high risk of bronchitis, it is possible to prevent the onset of bronchitis in adults and the elderly.
Claims
1. A nutritional composition for preventing bronchitis, comprising N-acetylneuraminic acid as an active ingredient.
2. 2. The nutritional composition of claim 1, wherein the N-acetylneuraminic acid is bound to one or more of a protein, a peptide, an oligosaccharide, or a lipid.
3. 3. The nutritional composition according to claim 1 or 2, wherein the linkage of N-acetylneuraminic acid is an α2,6 linkage.
4. The nutritional composition according to claim 3, wherein the sugar chain containing N-acetylneuraminic acid is present as 6'-sialyllactose.
5. The nutritional composition according to claim 3, wherein the sugar chain containing N-acetylneuraminic acid is present as an N-linked sugar chain.
6. The nutritional composition according to claim 5, wherein the sugar chain containing N-acetylneuraminic acid is an α2,6 disialo N-linked sugar chain.
7. The nutritional composition according to claim 6, wherein the α2,6 disialo N-linked glycan has the structure shown in (1) or (2) below. (1) Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc (2) Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc
8. A nutritional composition according to any one of claims 1 to 7, for use in infants and young children.
9. A food or drink for preventing bronchitis, comprising the nutritional composition for preventing bronchitis according to any one of claims 1 to 8.
10. A pharmaceutical for preventing bronchitis, comprising the nutritional composition for preventing bronchitis according to any one of claims 1 to 8.
11. A method for producing a nutritional composition for infants, comprising the step of adding a glycan containing N-acetylneuraminic acid to a raw material for the composition, wherein the glycan containing N-acetylneuraminic acid is one or more selected from the group consisting of 6'-sialyllactose, a glycan having the structure shown in (1) below, and a glycan having the structure shown in (2) below. (1) Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc (2) Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc
12. The method for producing a nutritional composition for infants according to claim 11, wherein the step of adding a sugar chain containing N-acetylneuraminic acid to the composition raw material is a step of adding the 6'-sialyllactose to the composition raw material so that the amount of the 6'-sialyllactose is 46.9 mg / 100 g solid or more.
13. The method for producing a nutritional composition for infants according to claim 11, wherein the step of adding sugar chains containing N-acetylneuraminic acid to the composition raw material is a step of adding sugar chains having the structures shown in (1) and (2) in a total amount of 0.198 μmol / 100 g solid or more.
14. The method for producing a nutritional composition for infants according to claim 11, wherein the step of adding a sugar chain containing N-acetylneuraminic acid to the composition raw material is a step of adding the sugar chain shown in (1) above so as to be 0.0728 μmol / 100 g solid or more.
15. The method for producing a nutritional composition for infants according to claim 11, wherein the step of adding a sugar chain containing N-acetylneuraminic acid to the composition raw material is a step of adding the sugar chain shown in (2) above so as to give a concentration of 0.0935 μmol / 100 g solid or more.
16. A method for producing a nutritional composition for infants, comprising the step of adding an α2,6 disialo N-linked glycan to the composition raw material so that the concentration is 0.198 μmol / 100 g solid or more.
